These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20093941)

  • 21. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD.
    Flapper BC; Schoemaker MM
    Dev Med Child Neurol; 2008 Apr; 50(4):294-9. PubMed ID: 18352997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
    Pierce D; Katic A; Buckwalter M; Webster K
    J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.
    Mattos P; Louzã MR; Palmini AL; de Oliveira IR; Rocha FL
    J Atten Disord; 2013 Jul; 17(5):444-8. PubMed ID: 22334621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder.
    Corkum P; Panton R; Ironside S; Macpherson M; Williams T
    J Pediatr Psychol; 2008 May; 33(4):368-79. PubMed ID: 18056144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neuropsychological assessment of the effectiveness of OROS-methylphenidate in attention deficit hyperactivity disorder].
    Rubio-Morell B; Martín-González R; Herreros-Rodríguez O; González-Pérez P; Hernández-Exposito S; Quintero-Fuentes I; Gracia-Marco R
    Rev Neurol; 2008 May 16-31; 46(10):602-8. PubMed ID: 18465700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
    BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylphenidate improves reading performance in children with attention deficit hyperactivity disorder and comorbid dyslexia: an unblinded clinical trial.
    Keulers EH; Hendriksen JG; Feron FJ; Wassenberg R; Wuisman-Frerker MG; Jolles J; Vles JS
    Eur J Paediatr Neurol; 2007 Jan; 11(1):21-8. PubMed ID: 17169593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Methylphenidate and sleep: Results of a multicentre study on a population of children with attention deficit hyperactivity disorder].
    Tomás Vila M; Aleu Pérez-Gramunt M; Beseler Soto B; Benac Prefasi M; Pantoja Martínez J; Pitarch Castellano I
    An Pediatr (Barc); 2010 Aug; 73(2):78-83. PubMed ID: 20605120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
    Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
    Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of methylphenidate on Internet video game play in children with attention-deficit/hyperactivity disorder.
    Han DH; Lee YS; Na C; Ahn JY; Chung US; Daniels MA; Haws CA; Renshaw PF
    Compr Psychiatry; 2009; 50(3):251-6. PubMed ID: 19374970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.
    Golubchik P; Sever J; Zalsman G; Weizman A
    Int Clin Psychopharmacol; 2008 Jul; 23(4):228-31. PubMed ID: 18446088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylphenidate effects on a laboratory aggression measure in children with ADHD.
    Casat CD; Pearson DA; Van Davelaar MJ; Cherek DR
    Psychopharmacol Bull; 1995; 31(2):353-6. PubMed ID: 7491391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.